Utility of the Asia-Pacific colorectal screening scoring system and the presence of metabolic syndrome components in screening for sporadic colorectal cancer

Table 1 Comparison of the colorectal tumor detection rates in patients in the different Asia-Pacific colorectal screening risk groups n (%)

Groups	AR (n = 88)	MR (n = 113)	HR (n = 18)
Colorectal tumor	14 (15.9)	41 (36.3)b	14 (77.8)bd
Non-advanced tumor	12 (13.6)	30 (26.5)a	9 (50)bc
Advanced tumor	2 (2.3)	11 (9.7)a	5 (27.8)bc

^aP < 0.05,

^bP < 0.01 vs AR group;

^cP < 0.05,

^dP < 0.01 vs MR group. AR: Average-risk; MR: Moderate-risk; HR: High-risk.

Table 2 Effect of the presence of metabolic syndrome components on the colorectal tumor detection rate n (%)

Groups	A (n = 52)	B (n = 39)	C (n = 40)	B + C (n = 79)
Colorectal tumor	10 (19.2)	22 (56.4)b	25 (62.5)b	47 (59.5)b
Non-advanced tumor	9 (17.3)	14 (35.9)a	16 (40)a	30 (38.0)a
Advanced tumor	1 (1.9)	8 (20.5)b	9 (22.5)b	17 (21.5)b

^aP < 0.05,

^bP < 0.01 vs group A.

Table 3 Comparison of the colorectal tumor detection rates for different screening programs n (%)

Groups	Patient volunteered (D) (n = 41)	Doctor recommended (E) (n = 126)	APCS MR/HR (F) (n = 131)	APCS MR/HR with obesity (G) (n = 79)
Colorectal tumor	6 (14.6)	46 (36.5)b	55 (42.0)b	47 (59.5)bde
Non-advanced tumor	5 (12.2)	33 (26.2)	39 (29.8)a	30 (38.0)b
Advanced tumor	1 (2.4)	13 (10.3)	16 (12.2)	17 (21.5)bc

^aP < 0.05,

^bP < 0.01 vs group D;

^cP < 0.05,

^dP < 0.01 vs group E;

^eP < 0.05 vs group F. APCS: Asia-Pacific colorectal screening; MR: Moderate-risk; HR: High-risk.